Dapagliflozin in People With Kidney Failure on Peritoneal Dialysis
Tests dapagliflozin in people with end-stage kidney disease receiving peritoneal dialysis.
Plain-language title generated from the registry record
Registry title: Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
Key facts
- Where
- Nizwa, OmanSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 13 or older who are on long-term peritoneal dialysis and still pass some urine. They will take dapagliflozin 10 mg once daily for six months.
- Age
- 13 years or older
- Sex
- All genders can join.
- Disease stage
- End-stage kidney disease on chronic peritoneal dialysis, with or without diabetes. Urine output must be 150 ml/24 hours or more.
- Earlier treatment
- Must be on chronic peritoneal dialysis. Must not have had peritonitis related to the dialysis catheter in the last 3 months.
Main reasons for not taking part
- Type I diabetes mellitus
- Recurrent urinary tract infections or peripheral vascular disease
- Urine output less than 150 ml/24 hours
- Recurrent low blood sugar episodes
- Acute or chronic liver disease
This trial only enrols participants on dialysis. The registry sentence this rests on: * All patients undergoing chronic Peritoneal Dialysis.
Read by machine on 9 November 2026.
Where in Oman
- Jehad Badawi AL LAHAMNizwa, OmanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oman Ministry of Health
- Trial code
- NCT07491042
- Record updated
- 24 March 2026
- Original description
This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis.Read full original descriptionShow less
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients: A Six-month Prospective .Study
This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis.
Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laboratory parameters will be assessed at baseline, then three and six months after drug initiation.
The primary outcomes are:1- change in ultrafiltration volume, 2- change in Kt/V (dialysis adequacy), 3. Change in the mean 24-hour urine volume.
Inclusion: o age equal to or more than13 years; All genders; All patients undergoing chronic Peritoneal Dialysis; Urine output equal or more than 150 ml/24 hours.
Exclusion: o Age less than 13 years; Patients with type I diabetes mellitus; Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D); Patients with urine output less than 150 ml/24hours; Patients with recurrent hypoglycemic episodes; Patients with acute or chronic liver disease,; Patients who refuse to participate in the study; peritoneal Dialysis catheter (PDC) related peritonitis in last 3 months.